Trial participants
From 22 January 2022 to 23 April 2022, 804 participants who visited the COVID-19 clinic were assessed for eligibility. Of these, 152 participants declined to participate, 84 consented to another parallel clinical study, and 568 did not meet the inclusion criteria and were excluded. Ultimately, 136 participants who met the inclusion criteria were randomized, with 68 receiving CCP-FPV and 68 receiving sotrovimab. No participants were lost to follow-up throughout the study period (